News NICE recommends Celgene pancreatic cancer drug Abraxane finally gets NHS funding following price cut.
News UK and US spearhead search for drugs targeting RAS mutations Cancer Research UK and its Cancer Research Technology Pioneer Fund have joined with the US National Cancer Institute (NCI) to test new molecules targeting RAS mutations.
News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News Shire's Onivyde pancreatic cancer drug approved in EU Drug approved in metastatic adenocarcinoma of the pancreas.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.